Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elimusertib + Pembrolizumab in Advanced Solid Tumors
NCT04095273Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of elimusertib in solid tumor, breast cancer, colorectal cancer (CRC) and 5 more, sponsored by Bayer. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Severity of Treatment Emergent Adverse Events and 2 more. Started Sep 2019; status: completed.
02
Drugs
elimusertib
03
Conditions
solid tumorbreast cancercolorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04095273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095273.